Multimodal treatment of resectable esophageal cancer Review
| Authors: | Waters, J.; Sewell, M.; Molena, D. |
| Review Title: | Multimodal treatment of resectable esophageal cancer |
| Abstract: | Background: The current guidelines for the treatment of esophageal cancer recommend a multimodal approach that includes chemotherapy, targeted therapy and immunotherapy, radiation, and surgery. Despite advances in treatment, rates of treatment failure, pathologic incomplete response, tumor metastasis, and death remain unacceptably high. Methods: This study was a narrative literature review using the terms “resectable esophageal cancer” and “multimodal therapy” to identify prospective trials of neoadjuvant radiation and chemotherapy, individually or combined with surgery, for esophageal cancer. Trials performed between 1984 and 2022 were identified and analyzed. Clinicaltrials.gov was queried to identify ongoing studies. Results: Twenty-one clinical studies were identified: 15 randomized controlled trials and 6 prospective nonrandomized trials. The results of the randomized trials suggest that multimodal therapy—in the form of neoadjuvant chemotherapy in combination with radiation or chemotherapy alone, followed by surgery—is associated with better rates of local disease control and partial clinical response and, potentially, longer survival than is surgery alone. Immunotherapy is an emerging option for the treatment of patients with esophageal cancer. Conclusions: The treatment of patients with resectable esophageal cancer is rapidly evolving. Although previous treatment options have had only limited benefits for patients, significant progress has been made during last 3 decades. The results of the available studies suggest that advances in the treatment of esophageal cancer have the potential to improve survival in these patients; however, questions remain regarding mechanisms of action, patient selection, and the use of personalized approaches that are based on genetics. © 2024 The Society of Thoracic Surgeons |
| Keywords: | treatment failure; review; multimodality cancer therapy; patient selection; side effect; phase 2 clinical trial; randomized controlled trial; radiotherapy; drug combination; surgery; neoadjuvant chemotherapy; clinical practice guideline; drug therapy; disease control; esophagus cancer; adverse drug reaction; therapy; drug comparison; human; male |
| Journal Title: | Annals of Thoracic Surgery |
| Volume: | 119 |
| Issue: | 1 |
| ISSN: | 0003-4975 |
| Publisher: | Elsevier Science, Inc. |
| Date Published: | 2025-01-01 |
| Start Page: | 70 |
| End Page: | 82 |
| Language: | English |
| DOI: | 10.1016/j.athoracsur.2024.04.034 |
| PUBMED: | 38777248 |
| PROVIDER: | scopus |
| PMCID: | PMC11579246 |
| DOI/URL: | |
| Notes: | The MSK Cancer Center Support Grant (P30 CA008748) is acknowledge in the PDF -- Corresponding authors is MSK author: Daniela Molena -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work